Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Meyer, Alexander von

Diagnosis

Official Journal of the Society to Improve Diagnosis in Medicine (SIDM)

Editor-in-Chief: Graber, Mark L. / Plebani, Mario

Ed. by Epner, Paul L. / Lippi, Giuseppe / Singh, Hardeep

Editorial Board: Basso , Daniela / Crock, Carmel / Croskerry, Pat / Dhaliwal, Gurpreet / Ely, John / Giannitsis, Evangelos / Katus, Hugo A. / Laposata, Michael / Lyratzopoulos, Yoryos / Maude, Jason / Newman-Toker, David / Sittig, Dean F. / Singhal, Geeta / Zwaan, Laura


CiteScore 2018: 0.69

SCImago Journal Rank (SJR) 2018: 0.359
Source Normalized Impact per Paper (SNIP) 2018: 0.424

Online
ISSN
2194-802X
See all formats and pricing
More options …

Atrial fibrillation: is there a role for cardiac troponin?

Alireza Sepehri ShamlooORCID iD: https://orcid.org/0000-0002-4894-8664 / Arash Arya / Angeliki Darma / Sotirios Nedios / Michael Döring / Andreas Bollmann / Nikolaos Dagres / Gerhard Hindricks
Published Online: 2020-01-09 | DOI: https://doi.org/10.1515/dx-2019-0072

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia, and its prevalence rate is expected to be doubled over the next decades. Despite the wide use of biomarkers in the management of different cardiac diseases such as myocardial infarction and heart failure, utilization of biomarkers in AF management is not routinely recommended by current guidelines. There is also growing evidence that higher levels of cardiac-specific troponin, as an intracellular protein involved in cardiomyocyte contraction, may be associated with the risk of incident and recurrent AF and its complications. In the present paper, we review the association between troponin and AF and propose clinical suggestions for use of troponin in the management of AF patients.

Keywords: atrial fibrillation; biomarker; risk score; troponin

References

  • 1.

    Hong KL, Glover BM. The impact of lifestyle intervention on atrial fibrillation. Curr Opin Cardiol 2018;33:14–9.PubMedCrossrefGoogle Scholar

  • 2.

    Berge T, Brynildsen J, Larssen HK, Onarheim S, Jenssen GR, Ihle-Hansen H, et al. Systematic screening for atrial fibrillation in a 65-year-old population with risk factors for stroke: data from the Akershus Cardiac Examination 1950 study. Europace 2017:1–7.Google Scholar

  • 3.

    Guerra F, Brambatti M, Nieuwlaat R, Marcucci M, Dudink E, Crijns H, et al. Symptomatic atrial fibrillation and risk of cardiovascular events: data from the Euro Heart Survey. Europace 2017;19:1922–9.CrossrefPubMedGoogle Scholar

  • 4.

    Zimetbaum P. Atrial fibrillation. Ann Intern Med 2017;166: Itc33–48.CrossrefPubMedGoogle Scholar

  • 5.

    Dagres N, Chao TF, Fenelon G, Aguinaga L, Benhayon D,Benjamin EJ, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Europace 2018;20:1399–421.PubMedCrossrefGoogle Scholar

  • 6.

    Shamloo AS, Dagres N, Arya A, Hindricks G. Atrial fibrillation: a review of modifiable risk factors and preventive strategies. Rom J Intern Med 2019;57:99–109.PubMedGoogle Scholar

  • 7.

    Wintgens L, Romanov A, Phillips K, Ballesteros G, Swaans M, Folkeringa R, et al. Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry. Europace 2018;20:1783–9.CrossrefPubMedGoogle Scholar

  • 8.

    Sepehri Shamloo A, Dagres N, Mussigbrodt A, Stauber A, Kircher S, Richter S, et al. Atrial fibrillation and cognitive impairment: new insights and future directions. Heart Lung Cir 2019.Google Scholar

  • 9.

    Chang KW, Hsu JC, Toomu A, Fox S, Maisel AS. Clinical applications of biomarkers in atrial fibrillation. Am J Med 2017;130:1351–7.PubMedCrossrefGoogle Scholar

  • 10.

    Wakula P, Neumann B, Kienemund J, Thon-Gutschi E, Stojakovic T, Manninger M, et al. CHA2DS2-VASc score and blood biomarkers to identify patients with atrial high-rate episodes and paroxysmal atrial fibrillation. Europace 2017;19:544–51.PubMedGoogle Scholar

  • 11.

    Reihani H, Sepehri Shamloo A, Keshmiri A. Diagnostic value of D-dimer in acute myocardial infarction among patients with suspected acute coronary syndrome. Cardiol Res 2018;9:17–21.CrossrefPubMedGoogle Scholar

  • 12.

    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–962.CrossrefPubMedGoogle Scholar

  • 13.

    Dan GA, Iliodromitis K, Scherr D, Marin F, Lenarczyk R, Estner HL, et al. Translating guidelines into practice for the management of atrial fibrillation: results of an European Heart Rhythm Association Survey. Europace 2018;20:1382–7.CrossrefPubMedGoogle Scholar

  • 14.

    Romanov A, Martinek M, Purerfellner H, Chen S, De Melis M, Grazhdankin I, et al. Incidence of atrial fibrillation detected by continuous rhythm monitoring after acute myocardial infarction in patients with preserved left ventricular ejection fraction: results of the ARREST study. Europace 2018;20:263–70.PubMedCrossrefGoogle Scholar

  • 15.

    Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:e139–228.CrossrefGoogle Scholar

  • 16.

    Filion KB, Agarwal SK, Ballantyne CM, Eberg M, Hoogeveen RC, Huxley RR, et al. High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2015;169:31–8.e3.CrossrefPubMedGoogle Scholar

  • 17.

    Fan Y, Zhao X, Li X, Li N, Hu X. Cardiac troponin and adverse outcomes in atrial fibrillation: a meta-analysis. Clin Chim Acta 2018;477:48–52.CrossrefPubMedGoogle Scholar

  • 18.

    Rienstra M, Yin X, Larson MG, Fontes JD, Magnani JW, McManus DD, et al. Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation. Am Heart J 2014;167:109–15.e2.CrossrefPubMedGoogle Scholar

  • 19.

    Schnabel RB, Wild PS, Wilde S, Ojeda FM, Schulz A, Zeller T, et al. Multiple biomarkers and atrial fibrillation in the general population. PLoS One 2014;9:e112486.CrossrefPubMedGoogle Scholar

  • 20.

    Hussein AA, Bartz TM, Gottdiener JS, Sotoodehnia N, Heckbert SR, Lloyd-Jones D, et al. Serial measures of cardiac troponin T levels by a highly sensitive assay and incident atrial fibrillation in a prospective cohort of ambulatory older adults. Heart Rhythm 2015;12:879–85.CrossrefGoogle Scholar

  • 21.

    Zhu K, Hung J, Divitini M, Murray K, Lim EM, St John A, et al. High-sensitivity cardiac troponin I and risk of incident atrial fibrillation hospitalisation in an Australian community-based cohort: The Busselton Health Study. Clin Biochem 2018;58:20–5.CrossrefGoogle Scholar

  • 22.

    Anegawa T, Kai H, Adachi H, Hirai Y, Enomoto M, Fukami A, et al. High-sensitive troponin T is associated with atrial fibrillation in a general population. Int J Cardiol 2012;156:98–100.CrossrefGoogle Scholar

  • 23.

    Horjen AW, Ulimoen SR, Enger S, Berge T, Ihle-Hansen H, Norseth J, et al. Impact of atrial fibrillation on levels of high-sensitivity troponin I in a 75-year-old population. Scand J Clin Lab Invest 2015;75:308–13.CrossrefGoogle Scholar

  • 24.

    Zehir R, Tekkesin AI, Haykir N, Velibey Y, Borklu EB, Gumusdag A. Peak troponin I level predicts new-onset atrial fibrillation in patients with myocardial infarction. Clin Invest Med 2016;39:E213–9.CrossrefPubMedGoogle Scholar

  • 25.

    Anatoĺevna RO, Veniaminovich FO, Mikhaylovich KS. Predictors of new-onset atrial fibrillation in elderly patients with coronary artery disease after coronary artery bypass graft. J Geriat Cardiol 2016;13:444.Google Scholar

  • 26.

    Ambrus DB, Benjamin EJ, Bajwa EK, Hibbert KA, Walkey AJ. Risk factors and outcomes associated with new-onset atrial fibrillation during acute respiratory distress syndrome. J Crit Care 2015;30:994–7.PubMedCrossrefGoogle Scholar

  • 27.

    Gal P, Parlak E, Schellings DA, Beukema R, ten Berg J,Adiyaman A, et al. Association of serial high sensitivity troponin T with onset of atrial fibrillation in ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Eur Heart J: Acute Cardiovas Care 2016;5:33–42.Google Scholar

  • 28.

    Scheitz JF, Erdur H, Haeusler KG, Audebert HJ, Roser M, Laufs U, et al. Insular cortex lesions, cardiac troponin, and detection of previously unknown atrial fibrillation in acute ischemic stroke: insights from the troponin elevation in acute ischemic stroke study. Stroke 2015;46:1196–201.CrossrefPubMedGoogle Scholar

  • 29.

    Parashar S, Kella D, Reid KJ, Spertus JA, Tang F, Langberg J, et al. New-onset atrial fibrillation after acute myocardial infarction and its relation to admission biomarkers (from the TRIUMPH registry). Am J Cardiol 2013;112:1390–5.PubMedCrossrefGoogle Scholar

  • 30.

    Koolen BB, Labout JA, Mulder PG, Gerritse BM, Rijpstra TA, Bentala M, et al. Association of perioperative troponin and atrial fibrillation after coronary artery bypass grafting. Interact Cardiovas Thorac Surg 2013;17:608–14.CrossrefGoogle Scholar

  • 31.

    Bai Y, Guo S-D, Liu Y, Ma C-S, Lip GY. Relationship of troponin to incident atrial fibrillation occurrence, recurrence after radiofrequency ablation and prognosis: a systematic review, meta-analysis and meta-regression. Biomarkers 2018;23:512–7.PubMedCrossrefGoogle Scholar

  • 32.

    Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace 2018;20:1231–42.CrossrefPubMedGoogle Scholar

  • 33.

    Hart RG, Pearce LA, Koudstaal PJ. Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial. Stroke 2004;35:948–51.PubMedCrossrefGoogle Scholar

  • 34.

    Hylek Elaine M. Biomarkers for prediction of stroke and bleeds in atrial fibrillation. Circulation 2019;139:772–4.PubMedCrossrefGoogle Scholar

  • 35.

    Bai Y, Guo SD, Shantsila A, Lip GY. Modelling projections for the risks related with atrial fibrillation in East Asia: a focus on ischaemic stroke and death. Europace 2018;20:1584–90.CrossrefPubMedGoogle Scholar

  • 36.

    Dietzel J, Piper SK, Ruschmann R, Wollboldt C, Usnich T, Hellwig S, et al. Impact of pre-admission oral anticoagulation on ischaemic stroke volume, lesion pattern, and frequency of intracranial arterial occlusion in patients with atrial fibrillation. Europace 2018;20:1758–65.PubMedCrossrefGoogle Scholar

  • 37.

    Engdahl J, Holmen A, Rosenqvist M, Stromberg U. A prospective 5-year follow-up after population-based systematic screening for atrial fibrillation. Europace 2018;20(Fi_3):f306–11.PubMedCrossrefGoogle Scholar

  • 38.

    Heidbuchel H, Dagres N, Antz M, Kuck KH, Lazure P, Murray S, et al. Major knowledge gaps and system barriers to guideline implementation among European physicians treating patients with atrial fibrillation: a European Society of Cardiology international educational needs assessment. Europace 2018;20: 1919–28.CrossrefGoogle Scholar

  • 39.

    Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 2016;37:1582–90.CrossrefGoogle Scholar

  • 40.

    Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, et al. Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48. Circulation 2019;139:760–71.PubMedCrossrefGoogle Scholar

  • 41.

    Vafaie M, Giannitsis E, Mueller-Hennessen M, Biener M, Makarenko E, Yueksel B, et al. High-sensitivity cardiac troponin T as an independent predictor of stroke in patients admitted to an emergency department with atrial fibrillation. PLoS One 2019;14:e0212278.CrossrefGoogle Scholar

  • 42.

    Stoyanov KM, Giannitsis E, Biener M, Mueller-Hennessen M, Arens K, Katus HA, et al. Prognostic value of elevated high-sensitivity cardiac troponin T in patients admitted to an emergency department with atrial fibrillation. Europace 2018;20:582–8.CrossrefGoogle Scholar

  • 43.

    Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. Circulation 2012;126:2020–35.CrossrefPubMedGoogle Scholar

  • 44.

    Lippi G, Picanza A, Formentini A, Bonfanti L, Cervellin G. The concentration of troponin I is increased in patients with acute-onset atrial fibrillation. Int J Cardiol 2014;173:579–80.PubMedCrossrefGoogle Scholar

  • 45.

    Parwani AS, Boldt L-H, Huemer M, Wutzler A, Blaschke D, Rolf S, et al. Atrial fibrillation-induced cardiac troponin I release. Int J Cardiol 2013;168:2734–7.CrossrefPubMedGoogle Scholar

  • 46.

    Murer M, Cuculi F, Toggweiler S, Weberndoerfer V, Young M, Kobza R. Elevated high-sensitivity troponin does not indicate the presence of coronary artery disease in patients presenting with supraventricular tachycardia. Cardiol J 2017;24:642–8.CrossrefPubMedGoogle Scholar

  • 47.

    Soerensen NA, Shah AS, Ojeda FM, Peitsmeyer P, Zeller T, Keller T, et al. High-sensitivity troponin and novel biomarkers for the early diagnosis of non-ST-segment elevation myocardial infarction in patients with atrial fibrillation. Eur Heart J: Acute Cardiovas Care 2016;5:419–27.Google Scholar

  • 48.

    Liebetrau C, Weber M, Tzikas S, Palapies L, Möllmann H, Pioro G, et al. Identification of acute myocardial infarction in patients with atrial fibrillation and chest pain with a contemporary sensitive troponin I assay. BMC Med 2015;13:169.CrossrefPubMedGoogle Scholar

  • 49.

    Mariathas M, Gemmell C, Olechowski B, Nicholas Z, Mahmoudi M, Curzen N. High sensitivity troponin in the management of tachyarrhythmias. Cardiovas Revascular Med 2018;19(5, Part A):487–92.CrossrefGoogle Scholar

  • 50.

    Buttner P, Schumacher K, Dinov B, Zeynalova S, Sommer P, Bollmann A, et al. Role of NT-proANP and NT-proBNP in patients with atrial fibrillation: association with atrial fibrillation progression phenotypes. Heart Rhythm 2018;15:1132–7.PubMedCrossrefGoogle Scholar

  • 51.

    Yao Y, Yao W, Bai R, Lu ZH, Tang RB, Long DY, et al. Plasma homocysteine levels predict early recurrence after catheter ablation of persistent atrial fibrillation. Europace 2017;19:66–71.PubMedGoogle Scholar

  • 52.

    Fiala M, Bulkova V, Sknouril L, Nevralova R, Toman O, Januska J, et al. Functional improvement after successful catheter ablation for long-standing persistent atrial fibrillation. Europace 2017;19:1781–9.PubMedGoogle Scholar

  • 53.

    Sepehri Shamloo A, Dagres N, Dinov B, Sommer P, Husser-Bollmann D, Bollmann A, et al. Is epicardial fat tissue associated with atrial fibrillation recurrence after ablation? A systematic review and meta-analysis. Int J Cardiol Heart Vasc 2019;22:132–8.PubMedGoogle Scholar

  • 54.

    Zeemering S, Lankveld TA, Bonizzi P, Limantoro I, Bekkers S, Crijns H, et al. The electrocardiogram as a predictor of successful pharmacological cardioversion and progression of atrial fibrillation. Europace 2018;20:e96–104.CrossrefPubMedGoogle Scholar

  • 55.

    Das M, Loveday JJ, Wynn GJ, Gomes S, Saeed Y, Bonnett LJ, et al. Ablation index, a novel marker of ablation lesion quality: prediction of pulmonary vein reconnection at repeat electrophysiology study and regional differences in target values. Europace 2017;19:775–83.PubMedGoogle Scholar

  • 56.

    Kapur S, Kumar S, John RM, Stevenson WG, Tedrow UB, Koplan BA, et al. Family history of atrial fibrillation as a predictor of atrial substrate and arrhythmia recurrence in patients undergoing atrial fibrillation catheter ablation. Europace 2018;20:921–8.PubMedCrossrefGoogle Scholar

  • 57.

    Kim TH, Lee JS, Uhm JS, Joung B, Lee MH, Pak HN. High circulating adiponectin level is associated with poor clinical outcome after catheter ablation for paroxysmal atrial fibrillation. Europace 2018;20:1287–93.PubMedCrossrefGoogle Scholar

  • 58.

    Mesquita J, Ferreira AM, Cavaco D, Moscoso Costa F, Carmo P, Marques H, et al. Development and validation of a risk score for predicting atrial fibrillation recurrence after a first catheter ablation procedure – ATLAS score. Europace 2018;20(Fi_3):f428–35.CrossrefPubMedGoogle Scholar

  • 59.

    Kosich F, Schumacher K, Potpara T, Lip GY, Hindricks G, Kornej J. Clinical scores used for the prediction of negative events in patients undergoing catheter ablation for atrial fibrillation. Clin Cardiol 2019;42:320–9.PubMedCrossrefGoogle Scholar

  • 60.

    Jiang H, Wang W, Wang C, Xie X, Hou Y. Association of pre-ablation level of potential blood markers with atrial fibrillation recurrence after catheter ablation: a meta-analysis. Europace 2017;19:392–400.PubMedGoogle Scholar

  • 61.

    Miake J, Kato M, Ogura K, Iitsuka K, Okamura A, Tomomori T, et al. Pre-ablation levels of brain natriuretic peptide are independently associated with the recurrence of atrial fibrillation after radiofrequency catheter ablation in patients with nonvalvular atrial fibrillation. Heart Vessels 2019;34:517–26.PubMedCrossrefGoogle Scholar

  • 62.

    Latini R, Masson S, Pirelli S, Barlera S, Pulitano G, Carbonieri E, et al. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-Atrial Fibrillation Trial. J Interl Med 2011;269:160–71.CrossrefGoogle Scholar

  • 63.

    Nakanishi K, Fukuda S, Yamashita H, Hasegawa T, Kosaka M, Shirai N, et al. High-sensitive cardiac troponin T as a novel predictor for recurrence of atrial fibrillation after radiofrequency catheter ablation. Europace 2017;19:1951–7.PubMedCrossrefGoogle Scholar

  • 64.

    van den Bos EJ, Constantinescu AA, van Domburg RT, Akin S, Jordaens LJ, Kofflard MJ. Minor elevations in troponin I are associated with mortality and adverse cardiac events in patients with atrial fibrillation. Eur Heart J 2011;32:611–7.CrossrefPubMedGoogle Scholar

  • 65.

    Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 2012;125:1605–16.CrossrefPubMedGoogle Scholar

  • 66.

    Roldán V, Marín F, Díaz J, Gallego P, Jover E, Romera M, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost 2012;10:1500–7.PubMedCrossrefGoogle Scholar

  • 67.

    Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol 2014;63:52–61.CrossrefPubMedGoogle Scholar

  • 68.

    Naffaa ME, Nasser R, Manassa E, Younis M, Azzam ZS, Aronson D. Cardiac troponin-I as a predictor of mortality in patients with first episode acute atrial fibrillation. QJM 2017;110:507–11.PubMedCrossrefGoogle Scholar

About the article

Corresponding author: Alireza Sepehri Shamloo, MD, Department of Electrophysiology, Heart Center Leipzig at University of Leipzig, Strümpellstrasse 39, 04289 Leipzig, Germany, Phone: +49 341 8651413, Fax: +49 341 8651460


Received: 2019-10-11

Accepted: 2019-12-06

Published Online: 2020-01-09


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: AB, ND, and GH report research grants from Abbott and Boston Scientific to the institution without personal financial benefits. Other authors do not declare any conflict of interest.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Conflict of interest statement: AB, ND, and GH report research grants from Abbott and Boston Scientific to the institution without personal financial benefits. Other authors do not declare any conflict of interest.


Citation Information: Diagnosis, 20190072, ISSN (Online) 2194-802X, ISSN (Print) 2194-8011, DOI: https://doi.org/10.1515/dx-2019-0072.

Export Citation

©2020 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in